Shots:
- The US FDA has approved Jobevne, a biosimilar version of Avastin (bevacizumab) for IV administration
- Approval was based on extensive data showing Jobevne is similar to Avastin in PK, safety, efficacy, structure, & function across clinical & analytical studies
- Jobevne (VEGF inhibitor) is marketed under the brand name Abevmy in the EU & Canada, with approvals granted in Feb & Nov 2021, respectively
Ref: Biocon Biologics | Image: Biocon Biologics
Related News:- Biocon Biologics Partners with Civica to extend access of Insulin Aspart in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
